Protein engineering and design for drug delivery

Current Opinion in Structural Biology

Volumn 6, Issue 4, 1996, Pages 541-545

  Murphy, John R ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN; HYBRID PROTEIN; PLASMINOGEN ACTIVATOR; PSEUDOMONAS EXOTOXIN; RECOMBINANT PROTEIN;

CLINICAL TRIAL; DRUG DELIVERY SYSTEM; GENETIC ENGINEERING; HUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SKIN LYMPHOMA; T CELL LYMPHOMA;

EID: 0030220182     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-440X(96)80121-7     Document Type: Article

References (25)

1. Runge MS, Quertermous T, Zavodny PJ, Love TW, Bode C, Freitag M, Shaw S-Y, Huang PL, Chou C-C, Mullins D, et al. A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Natl Acad Sci USA. 88:1991;10337-10341.
2. of special interest Murphy JR, Van Der Spek JC. Targeting diphtheria toxin to growth factor receptors. Semin Cancer Biol. 6:1995;259-267 A summary of the protein engineering of diphtheria toxin which led to the development of targeted fusion protein cytotoxic biologic agents for the treatment of human disease.
3. 486 IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood. 79:1992;2547-2554.
4. 486 IL-2. Blood. 79:1992;175a.
5. Hesketh P, Caguioa P, Koh H, Dewey H, Facada A, McCaffrey R, Parker K, Nylen P, Woodworth T. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T cell lymphoma. J Clin Oncol. 11:1993;1682-1690.
6. of special interest Frankel A, Tagge EP, Willingham MC. Clinical trials of targeted toxins. Semin Cancer Biol. 6:1995;307-317 A summary of the results obtained from the clinical evaluation of targeted toxins that includes both immunotoxins (monoclonal antibodies cross-linked to fragments of plant or bacterial toxins) and fusion toxins (genetically engineered recombinant fusion proteins).
7. 389 IL-2. This study demonstrates that the pathogenesis of psoriasis is likely to be autoimmune in nature.
8. Kreitman RJ, Pastan I. Recombinant toxins. Adv Pharmacol. 28:1994;193-219.
9. Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for binding to the KDEL receptor. Biochem J. 307:1995;29-37.
10. of special interest Kreitman RJ, Pastan I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin Cancer Biol. 6:1995;297-306 A summary of the protein engineering of Pseudomonas exotoxin A which led to the development of targeted fusion proteins in this system.
11. Kreitman RJ, Puri RK, Lel P, Lee B, Pasten I. Site-specific conjugation to interleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity. Biochemistry. 33:1994;11637-11644.
12. Sprang SR, Bazan JF. Cytokine structural taxonomy and mechanisms of receptor engagement. Curr Opin Struct Biol. 3:1993;815-827.
13. of outstanding interest Kreitman RJ, Puri R, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci USA. 91:1994;6889-6893 A very interesting study in which the authors demonstrate that the organization of the structural gene encoding IL-4 can be circularly permutated. Importantly, variants with increased receptor binding affinity and cytotoxic potency were isolated and characterized. Since the fusion protein toxins are non-evolved proteins this study establishes an important paradigm for this field in the application of circular permutation to the design of these novel fusion proteins.
14. of special interest Kreitman RJ, Puri RK, Pastan I. Increased antitumor activity of a circularly permuted IL4-toxin in mice with IL4 receptor-bearing human carcinomas. Cancer Res. 55:1995;3357-3363 An interesting animal study which demonstrates that an IL-4 receptor targeted fusion protein in which the receptor binding domain has been circularly permutated has increased therapeutic efficacy in vivo.
15. Brinkman U, Reiter Y, Jung S-H, Lee B, Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment (dsFv). Proc Natl Acad Sci USA. 90:1993;7538-7542.
16. Jung S-H, Pastan I, Lee B. Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins. 19:1994;35-47.
17. y antigen. Semin Cancer Biol. 6:1995;289-295.
18. Siegall CB, Liggitt D, Chace D, Tepper M, Fell HP. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci USA. 91:1994;9514-9518.
19. Walker B, Bayley H. Key residues for membrane binding, oligomerization, and pore-forming activity of staphylococcal α-hemolysin identified by cysteine scanning mutagenesis and targeted chemical modification. J Biol Chem. 270:1995;23065-23071.
20. Walker B, Bayley H. A pore-forming protein with a protease-activated trigger. Protein Eng. 7:1994;91-97.
21. of special interest Bayley H. Pore-forming proteins with built-in triggers and switches. Bioorg Chem. 23:1995;340-345 An interesting review of the α-hemolysin-based pore forming proteins that can be activated in vitro by a variety of signals.
22. of special interest Panchal RG, Cusack E, Cheley S, Bayley H. Tumor protease-activated, pore-forming toxins from a combinatorial library. Nat Biotechnol. 14:1996;852-856 An interesting study in which overlap mutant α-hemolysins have been modified by insertion of sequences derived from a combinatorial library. Screening of this library in the presence of tumor associated proteases has resulted in the isolation of specific new in vitro activated pore-forming toxins.
23. of outstanding interest Haber E. Antibody targeting: a strategy for improving thrombolytic therapy. Sasahara A, Loscalzo J. New Therapeutic Agents in Thrombolysis. 1996;Marcel Dekker, New York, A useful summary of the development of antifibrin - urokinase fusion proteins in the development of new agents for thrombolytic therapy.
24. of special interest Runge MS, Harker LA, Bode C, Ruef J, Kelly AB, Marzec UM, Allen E, Caban R, Shaw SY, Haber E, Hanson SR. Increased thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation. 1996; An interesting animal study which demonstrates the increased potency of a targeted antifibrin - urokinase fusion protein plasminogen activator in vivo.
25. Bode C, Hudelmayer M, Mehwald P, Bauer S, Fretag M, Von Hodenberg E, Newell JB, Kübler W, Haber E, Runge MS. Fibrin targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin. Circulation. 90:1995;1956-1963.